The verifiable place to buy research peptides · Free shipping over $150
0

Research Reference · Metabolic & Weight-Loss Research

Bioglutide (NA-931)

A name used for NA-931, an investigational oral drug described by its developer as an IGF-1, GLP-1, GIP and glucagon receptor agonist, studied in weight-loss (obesity) research.

Last reviewed September 2026 4 published sources 3-minute read

At a glance

Bioglutide is a name used for NA-931, an investigational oral drug from Biomed Industries described as a quadruple agonist of the IGF-1, GLP-1, GIP and glucagon receptors. Results so far come from company-presented conference abstracts. Its chemical structure is not given in these sources, so no laboratory can verify material sold under the name — which is why we do not sell it.

TypeInvestigational oral drug (NA-931)
Studied forObesity & type 2 diabetes
Evidence stagePhase 1–2 conference abstracts
Human dataCompany-reported; not fully peer-reviewed

What it’s studied for

Four-receptor design

Described as activating IGF-1, GLP-1, GIP and glucagon receptors — one more than triple agonists such as retatrutide. 2

Developer description

Oral route

Developed as an oral drug, unlike injectable semaglutide and tirzepatide. 2

Human · phase 1

Weight reduction

Dose-dependent weight reductions reported in phase 1; a 13-week phase 2 study is registered. 2,3,4

Human · abstracts

Muscle preservation

An ADA 2025 abstract reports weight reduction without muscle loss. 1

Human · abstract

Not currently stocked

This page is a research reference. Every product we do carry is third-party tested with a batch-matched COA.

Browse research peptides

How it works

NA-931 is being developed by Biomed Industries, Inc. as an oral treatment for obesity and type 2 diabetes. The company describes it as activating four receptors — IGF-1, GLP-1, GIP and glucagon. 2

In the published phase 1 abstract, a 28-day multiple-ascending-dose study reported dose-dependent weight reductions, continued into an open-label extension to 12 weeks, with treatment-emergent adverse events rated insignificant or mild. 2 A 13-week, randomized, placebo-controlled phase 2 study is registered as NCT06564753 and was presented at ENDO 2025, 3,4 and an ADA 2025 abstract reported weight reduction without muscle loss. 1

All of this is company-presented conference data; we found no full peer-reviewed paper. The molecular formula and structure are not given in these sources and we found no published CAS number, so there is no reference standard a third-party laboratory could test against. That breaks the batch-matched COA promise every product here rests on, so we do not sell it — and material sold elsewhere under this name cannot be checked against the compound in the trials.

Related research

RetatrutideTriple agonist TirzepatideDual agonist SemaglutideGLP-1 only

Frequently asked questions

What is NA-931?
The development code for the investigational drug sold online under the name “bioglutide”, developed by Biomed Industries, Inc.
Why don’t you sell bioglutide?
Its structure is not published in the available sources, so no lab can confirm the identity of a batch. We only sell peptides with a batch-matched, third-party certificate of analysis.
How is it different from retatrutide?
Retatrutide is an injectable peptide targeting three receptors; NA-931 is described as an oral drug targeting four, adding IGF-1.
Is NA-931 approved?
No. It is investigational, with phase 1 and phase 2 results presented as conference abstracts.
Is bioglutide a peptide?
The developer’s structure is not given in the published sources, so we cannot confirm what kind of molecule it is.

Identifiers

Name Bioglutide (name used online) · NA-931
Developer Biomed Industries, Inc.
Class (as described) Oral IGF-1 / GLP-1 / GIP / glucagon receptor agonist
Molecular formula Not given in the published sources
CAS number None found
Trial registry NCT06564753 (phase 2)
Status Investigational — not an approved drug

PubChem has no record for NA-931 or bioglutide. Trial status checked on ClinicalTrials.gov.

Research timeline

  1. 2025Phase 1 results published as an Endocrine Practice abstract. 2
  2. 2025ADA abstract: weight reduction without muscle loss. 1
  3. 2025ENDO abstract on the 13-week phase 2 study (NCT06564753). 3,4

Key studies

StudyModelWhat it found
Tran 2025 2 Human · phase 1 (abstract) Dose-dependent weight reductions over 28 days and a 12-week extension; adverse events mild.
ENDO 2025 3 Human · phase 2 (abstract) 13-week randomized, placebo-controlled study in adults with obesity.
ADA 2025 1 Human (abstract) Weight reduction without muscle loss, as reported by the developer.

Sources

  1. 143-OR: NA-931, a Novel Quadruple IGF-1-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss. Diabetes (American Diabetes Association), 2025. Conference abstract
  2. Phase 1 Clinical Trials Results of NA-931, a Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist for the Treatment of Obesity. Tran L. Endocr Pract, 2025. Conference abstract
  3. SAT-713: Phase 2 Clinical Trials of NA-931 to Study Subjects Who Are Obese With At Least One Weight-related Comorbid Condition. J Endocr Soc, 2025. Conference abstract
  4. Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition (NCT06564753). ClinicalTrials.gov. Trial registry
For Research Use Only. This page summarizes published scientific research for educational purposes. It is not medical advice and does not promote, recommend, or describe any human or animal use. Products referenced are sold strictly for laboratory research and are not for human consumption.

Last reviewed September 2026 by Midwest Compounds. Every source above was checked against its original publication.